Literature DB >> 31220352

Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.

Runping Liu1, Jason D Kang1, R Balfour Sartor2, Masoumeh Sikaroodi3, Andrew Fagan4, Edith A Gavis4, Huiping Zhou1, Phillip B Hylemon1, Jeremy W Herzog2, Xiaojiaoyang Li1, Robert H Lippman5, Javier Gonzalez-Maeso6, James B Wade7, Siddhartha Ghosh8, Emily Gurley1, Patrick M Gillevet3, Jasmohan S Bajaj4.   

Abstract

Cirrhosis and hepatic encephalopathy (HE) is associated with an altered gut-liver-brain axis. Fecal microbial transplant (FMT) after antibiotics improves outcomes in HE, but the impact on brain function is unclear. The aim of this study is to determine the effect of colonization using human donors in germ-free (GF) mice on the gut-liver-brain axis. GF and conventional mice were made cirrhotic using carbon tetrachloride and compared with controls in GF and conventional state. Additional GF mice were colonized with stool from controls (Ctrl-Hum) and patients with cirrhosis (Cirr-Hum). Stools from patients with HE cirrhosis after antibiotics were pooled (pre-FMT). Stools from the same patients 15 days after FMT from a healthy donor were also pooled (post-FMT). Sterile supernatants were created from pre-FMT and post-FMT samples. GF mice were colonized using stools/sterile supernatants. For all mice, frontal cortex, liver, and small/large intestines were collected. Cortical inflammation, synaptic plasticity and gamma-aminobutyric acid (GABA) signaling, and liver inflammation and intestinal 16s ribosomal RNA microbiota sequencing were performed. Conventional cirrhotic mice had higher degrees of neuroinflammation, microglial/glial activation, GABA signaling, and intestinal dysbiosis compared with other groups. Cirr-Hum mice had greater neuroinflammation, microglial/glial activation, and GABA signaling and lower synaptic plasticity compared with Ctrl-Hum mice. This was associated with greater dysbiosis but no change in liver histology. Pre-FMT material colonization was associated with neuroinflammation and microglial activation and dysbiosis, which was reduced significantly with post-FMT samples. Sterile pre-FMT and post-FMT supernatants did not affect brain parameters. Liver inflammation was unaffected.
Conclusion: Fecal microbial colonization from patients with cirrhosis results in higher degrees of neuroinflammation and activation of GABAergic and neuronal activation in mice regardless of cirrhosis compared with those from healthy humans. Reduction in neuroinflammation by using samples from post-FMT patients to colonize GF mice shows a direct effect of fecal microbiota independent of active liver inflammation or injury.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31220352      PMCID: PMC6923631          DOI: 10.1002/hep.30827

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  50 in total

1.  Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Christine M Schubert; Douglas M Heuman; James B Wade; Douglas P Gibson; Allyne Topaz; Kia Saeian; Muhammad Hafeezullah; Debulon E Bell; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Melanie B White; Arun J Sanyal
Journal:  Gastroenterology       Date:  2010-02-20       Impact factor: 22.682

2.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

3.  Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection.

Authors:  Stephan J Ott; Georg H Waetzig; Ateequr Rehman; Jacqueline Moltzau-Anderson; Richa Bharti; Juris A Grasis; Liam Cassidy; Andreas Tholey; Helmut Fickenscher; Dirk Seegert; Philip Rosenstiel; Stefan Schreiber
Journal:  Gastroenterology       Date:  2016-11-17       Impact factor: 22.682

4.  Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Oliviero Riggio; Lorenzo Ridola; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Federica Moscucci; Manuela Merli
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-15       Impact factor: 11.382

5.  Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.

Authors:  J S Bajaj; A J Sanyal; D Bell; H Gilles; D M Heuman
Journal:  Aliment Pharmacol Ther       Date:  2010-02-05       Impact factor: 8.171

6.  A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Authors:  Barjesh Chander Sharma; Praveen Sharma; Manish Kumar Lunia; Siddharth Srivastava; Rohit Goyal; S K Sarin
Journal:  Am J Gastroenterol       Date:  2013-07-23       Impact factor: 10.864

7.  Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Authors:  Dae Joong Kang; Naga S Betrapally; Siddhartha A Ghosh; R Balfour Sartor; Phillip B Hylemon; Patrick M Gillevet; Arun J Sanyal; Douglas M Heuman; Daniel Carl; Huiping Zhou; Runping Liu; Xiang Wang; Jing Yang; Chunhua Jiao; Jeremy Herzog; H Robert Lippman; Masoumeh Sikaroodi; Robert R Brown; Jasmohan S Bajaj
Journal:  Hepatology       Date:  2016-07-29       Impact factor: 17.425

8.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

Review 9.  Ammonia toxicity: from head to toe?

Authors:  Srinivasan Dasarathy; Rajeshwar P Mookerjee; Veronika Rackayova; Vinita Rangroo Thrane; Balasubramaniyan Vairappan; Peter Ott; Christopher F Rose
Journal:  Metab Brain Dis       Date:  2016-12-24       Impact factor: 3.584

Review 10.  Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology.

Authors:  Roger F Butterworth
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

View more
  27 in total

1.  Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis.

Authors:  Jasmohan S Bajaj; Masoumeh Sikaroodi; Andrew Fagan; Douglas Heuman; HoChong Gilles; Edith A Gavis; Michael Fuchs; Javier Gonzalez-Maeso; Shahzor Nizam; Patrick M Gillevet; James B Wade
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-28       Impact factor: 4.052

Review 2.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 3.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

4.  Reduced alcohol preference and intake after fecal transplant in patients with alcohol use disorder is transmissible to germ-free mice.

Authors:  Jennifer T Wolstenholme; Justin M Saunders; Maren Smith; Jason D Kang; Phillip B Hylemon; Javier González-Maeso; Andrew Fagan; Derrick Zhao; Masoumeh Sikaroodi; Jeremy Herzog; Amirhossein Shamsaddini; Marcela Peña-Rodríguez; Lianyong Su; Yun-Ling Tai; Jing Zheng; Po-Cheng Cheng; R Balfour Sartor; Patrick M Gillevet; Huiping Zhou; Jasmohan S Bajaj
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

5.  Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.

Authors:  Jasmohan S Bajaj; Nita Salzman; Chathur Acharya; Hajime Takei; Genta Kakiyama; Andrew Fagan; Melanie B White; Edith A Gavis; Mary L Holtz; Michael Hayward; Hiroshi Nittono; Phillip B Hylemon; I Jane Cox; Roger Williams; Simon D Taylor-Robinson; Richard K Sterling; Scott C Matherly; Michael Fuchs; Hannah Lee; Puneet Puri; R Todd Stravitz; Arun J Sanyal; Lola Ajayi; Adrien Le Guennec; R Andrew Atkinson; Mohammad S Siddiqui; Velimir Luketic; William M Pandak; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  JCI Insight       Date:  2019-12-19

Review 6.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 7.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

8.  Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats.

Authors:  Shao-Jung Hsu; Chihao Zhang; Jain Jeong; Seong-Il Lee; Matthew McConnell; Teruo Utsumi; Yasuko Iwakiri
Journal:  Gastroenterology       Date:  2020-11-20       Impact factor: 22.682

9.  Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs.

Authors:  Jun Weng; Xu Han; Fanhong Zeng; Yue Zhang; Lei Feng; Lei Cai; Kangyan Liang; Shusong Liu; Shao Li; Gongbo Fu; Min Zeng; Yi Gao
Journal:  Theranostics       Date:  2021-06-11       Impact factor: 11.556

10.  Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis.

Authors:  Yuan Zhang; Jason D Kang; Derrick Zhao; Siddartha S Ghosh; Yanyan Wang; Yunling Tai; Javier Gonzalez-Maeso; Masoumeh Sikaroodi; Patrick M Gillevet; H Robert Lippman; Phillip B Hylemon; Huiping Zhou; Jasmohan S Bajaj
Journal:  Front Physiol       Date:  2021-06-25       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.